Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHARBEVACOL: Tailored Bevacizumab in First-line Metastatic Colorectal Cancer
NCT06642844Phase 3Recruiting
- Sponsor
- University Hospital Tours
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in colorectal cancer (metastatic) (mCRC) (2 arms), sponsored by University Hospital Tours. Primary endpoint: Progression-Free Survival. Started Mar 2025; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT06642844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06642844.